Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[VEXAS syndrome].

Zeitschrift fur Rheumatologie·2025
Same author

[Use of IL-1 inhibitors in the treatment of familial Mediterranean fever in pediatric rheumatology].

Zeitschrift fur Rheumatologie·2025
Same author

[Diagnosis and treatment of ANCA-associated vasculitis : S3 guideline of the German Society for Rheumatology and Clinical Immunology e. V. (DGRh) and German Society for Internal Medicine e. V. (DGIM), German Society for Nephrology e. V. (DGfN), German Society for ENT Medicine and Head and Neck Surgery e. V. (DGHNO-KHC), German Ophthalmological Society e. V. (DOG), German Society for Neurology e. V. (DGN), German Society for Pneumology and Respiratory Medicine e. V. (DGP), German Society for Pathology e. V. (DGP), German Radiological Society, Society for Medical Radiology e. V. (DRG), Federal Association of German Pathologists, Federal Kidney Association e. V., German Rheumatism League Federal Association e. V.]

Zeitschrift fur Rheumatologie·2025
Same author

[Diagnosis and treatment of ANCA-associated vasculitis : SHORT VERSION of the S3 guideline of the German Society for Rheumatology and Clinical Immunology e. V. (DGRh) and German Society for Internal Medicine e. V. (DGIM), German Society for Nephrology e. V. (DGfN), German Society for Otorhinolaryngology and Head and Neck Surgery e. V. (DGHNO-KHC), German Ophthalmological Society e. V. (DOG), German Society for Neurology e. V. (DGN), German Society for Pneumology and Respiratory Medicine e. V. (DGP), German Society for Pathology e. V. (DGP), German Radiological Society, Society for Medical Radiology e. V. (DRG), Federal Association of German Pathologists, Federal Kidney Association e. V., German Rheumatism League Federal Association e. V.]

Zeitschrift fur Rheumatologie·2025
Same author

Castleman's disease in the rheumatological practice.

Zeitschrift fur Rheumatologie·2024
Same author

Unravelling the clinical heterogeneity of undefined recurrent fever over time in the European registries on Autoinflammation.

Pediatric rheumatology online journal·2024

Related Experiment Video

Updated: Jun 10, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

[IL-1 antagonists].

I Kötter1, G Horneff

  • 1Interdisziplinäres Zentrum für Rheumatologie, Klinische Immunologie und Autoimmunerkrankungen (INDIRA) und Medizinische Universitätsklinik Abt. II, Universistätsklinikum Tübingen, 72076 Tübingen, Deutschland. ina.koetter@med.uni-tuebingen.de

Zeitschrift Fur Rheumatologie
|August 13, 2010
PubMed
Summary
This summary is machine-generated.

Interleukin-1 (IL-1) drives inflammation and joint destruction in rheumatoid arthritis (RA). Newer IL-1 antagonists show promise for RA, but current data is limited, especially for patients unresponsive to TNF blockers.

More Related Videos

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
08:40

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

Published on: March 14, 2016

Related Experiment Videos

Last Updated: Jun 10, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
08:40

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

Published on: March 14, 2016

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Interleukin-1 (IL-1) is a key cytokine in the pathogenesis of inflammatory and autoimmune diseases like rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).
  • IL-1 contributes to inflammation and the destruction of cartilage and bone, making it a significant target for therapeutic intervention.
  • Tumor necrosis factor-alpha (TNF-alpha) and IL-1 are critical cytokines in RA pathogenesis.

Purpose of the Study:

  • To review the role of IL-1 in RA and JIA pathogenesis.
  • To evaluate the efficacy and application of IL-1 antagonists in treating RA and related inflammatory conditions.
  • To highlight the limited data on newer IL-1 antagonists, such as canakinumab, in RA, particularly in patients refractory to TNF blockers.

Main Methods:

  • Review of existing literature on IL-1, TNF-alpha, and their antagonists in inflammatory diseases.
  • Analysis of clinical trial data and retrospective studies on Anakinra, canakinumab, and rilonacept.
  • Comparison of the efficacy of IL-1 antagonists with TNF blockers in RA treatment.

Main Results:

  • Anakinra, an IL-1 receptor antagonist, is less effective for RA than TNF blockers and is primarily used for IL-1-mediated diseases.
  • Newer IL-1 antagonists, canakinumab (anti-IL-1beta antibody) and rilonacept (fusion protein), are approved for cryopyrin-associated periodic syndromes (CAPS).
  • Limited evidence exists for canakinumab in RA, with a retrospective analysis showing only 8% of anti-TNF pretreated patients achieving ACR 20 response.

Conclusions:

  • While IL-1 is crucial in RA pathogenesis, current IL-1 antagonists have shown limited success in RA compared to TNF blockers.
  • Anakinra is more suited for autoinflammatory syndromes and JIA than RA.
  • Further prospective studies are needed to establish the efficacy of newer IL-1 antagonists like canakinumab for RA, especially in patients who have failed TNF antagonist therapy.